Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

ENZOLYTICS, INC.

2000 North Central Expressway, Suite 104 Plano, TX 75074

(972)-292-9414

www.enzolytics.com

harry@enzolytics.co

m SIC Code 541711

Quarterly Report
For the Period Ending: June 30, 2022 (the "Reporting Period")

As of June 30, 2022, the number of shares outstanding of our Common Stock was: 2,830,345,953

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 2,797,935,953.

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 2,797,935,953.

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control[1] of the company has occurred over this reporting period: Yes: ☐

No: ☒

[1] "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities and the dates of the name changes.

The exact name of the issuer is: **Enzolytics, Inc.**

Formerly	Date changed
Immunotech Laboratories, Inc	September 11, 2017
Eco-Petroleum Solutions, Inc.	November 16, 2012
Structural Enhancement Technologies Corp.	May 10, 2010
Extreme Mobile Coatings Worldwide Corp.	February 23, 2009
Extreme Mobile Coatings Corp., Ltd.	October 10, 2008
Falcon Media Services, Ltd.	November 24, 2004
T&T Homes Limited	July 28, 2004

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

State / Jurisdiction of Incorporation:	United Kingdom Domiciled to Delaware February 23, 2009 Re-Domiciled to Wyoming May 21, 2020 Re-Domiciled to Delaware November 4, 2020 (currently Delaware - active)
Date Incorporated:	July 28, 2004

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:
None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:
None

The address(es) of the issuer's principal executive office:

Enzolytics, Inc
2000 North Central Expressway, Suite 104
Plano, Texas 75074

The address(es) of the issuer's principal place of business:
Check box if principal executive office and principal place of business are the same address: ☐

Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-4478

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?
Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below: **N/A**

2) Security Information

Trading symbol:	ENZC PK
Exact title and class of securities outstanding:	Common
CUSIP:	294112107
Par or stated value:	.0001
Total shares authorized:	3,000,000,000 as of date: 6/30/2022
Total shares outstanding:	2,830,435,953 as of date: 6/30/2022

Number of shares in the Public Float[2]: 2,313,596,368 as of date: 6/30/2022
Total number of shareholders of record: 195 as of date: 6/30/2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: N/A
Exact title and class of securities outstanding: Series A Preferred
CUSIP: N/A
Par or stated value: .0001
Total shares authorized: 60,000,000 as of date: 6/30/2022
Total shares outstanding: 60,000,000 as of date: 6/30/2022
Number of shares in the Public Float[3]: 0 as of date: 6/30/2022
Total number of shareholders of record: 4 as of date: 6/30/2022

Trading symbol: N/A
Exact title and class of securities outstanding: Series B Preferred
CUSIP: N/A
Par or stated value: .0001
Total shares authorized: 465,000,000 as of date: 6/30/2022
Total shares outstanding: 447,180,000 as of date: 6/30/2022
Number of shares in the Public Float[4]: 0 as of date: 6/30/2022
Total number of shareholders of record: 10 as of date: 6/30/2022

Trading symbol: N/A
Exact title and class of securities outstanding: Series C Preferred
CUSIP: N/A
Par or stated value: .0001
Total shares authorized: 10,000,000 as of date: 6/30/2022
Total shares outstanding: 941,078 as of date: 6/30/2022
Number of shares in the Public Float[5]: 0 as of date: 6/30/2022
Total number of shareholders of record: 2 as of date: 6/30/2022

Trading symbol: N/A
Exact title and class of securities outstanding: Series D Preferred
CUSIP: N/A
Par or stated value: .0001
Total shares authorized: 1,000,000 as of date: 6/30/2022
Total shares outstanding: 0 as of date: 6/30/2022
Number of shares in the Public Float[6]: 0 as of date: 6/30/2022
Total number of shareholders of record: 0 as of date: 6/30/2022
Trading symbol: N/A

Exact title and class of securities outstanding: Series E Preferred
CUSIP: N/A
Par or stated value: .0001
Total shares authorized: 10,000,000 as of date: 6/30/2022
Total shares outstanding: 2,500,000 as of date: 6/30/2022
Number of shares in the Public Float[7]: 0 as of date: 6/30/2022

[2] "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

[3] "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

[4] "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

[5] "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

[6] "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

[7] "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons

[8] To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act..

Total number of shareholders of record: 1 as of date: 06/30/2022

Transfer Agent

Name: Empire Stock Transfer, Inc.
Address: 1859 Whitney Mesa Dr.
Henderson NV 89014
Phone: (702) 818-5898
Email: brian@empirestock.com

Is the Transfer Agent registered under the Exchange Act?[8] Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End: Opening Balance Date 12/31/2020 Common: 2,797,935,953 Preferred A: 60,000,000 Preferred B: 445,180,000 Preferred C: 941,078 Preferred D: 0 Preferred E: 0			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	**Transaction type (e.g. new issuance, cancellation shares returned to treasury)**	**Number of Shares Issued (or cancelled)**	**Class of Securities**	**Value of shares issued ($/per share) at Issuance**	**Were the shares issued at a discount to market price at the time of issuance? (Yes/No)**	**Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).**	**Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided**	**Restricted or Unrestricted as of this filing.**	**Exemption or Registration Type.**
June 1, 2021	Issuance	1,250,000	Series E	.0001	no	Valentin Dimitrov	Cash	Restricted	Registration
June 16, 2021	Issuance	1,250,000	Series E	.0001	no	Valentin Dimitrov	Cash	Restricted	Registration
August 16, 2021	Issuance	400,000	Series B	.0001	no	Denitsa Stoilova Sidoroa	Stock exchange	Restricted	Registration
August 16, 2021	Issuance	400,000	Series B	.0001	no	Volen Nikolov Sidoroa	Stock exchange	Restricted	Registration
August 16, 2021	Issuance	100,000	Series B	.0001	no	Ivan Kostadiv Elandiev	Stock exchange	Restricted	Registration
August 16, 2021	Issuance	400,000	Series B	.0001	no	Desislav Slavov Chukolov	Stock exchange	Restricted	Registration

August 16, 2021	Issuance	700,000	Series B	.0001——	no	Luchear Bogomil	Stock exchange	Restricted	Registration

Shares Outstanding on Date of This Report:	
Date: 09/07/2022	Ending Balance
	Common: 2,830,435,953
	Preferred A: 60,000,000
	Preferred B: 447,180,000
	Preferred C: 941,078
	Preferred D: 0
	Preferred E: 2,500,000

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2019, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2017 through September 30, 2019 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above: **None**

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: x

Date of Note Issuance	Outstanding Balance ($)	Principal Amount at Issuance ($)	Interest Accrued ($)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)

Use the space below to provide any additional details, including footnotes to the table above:

1. The note carries an interest rate of 10 percent per annum, and may be either repaid, at the election of the note holder in cash plus the issuance of shares of common stock of the Company in the amount of $30,000 in value, or by the conversion of the principal and interest due into a total of $45,000 in value of common stock of the Company.
2. As a result of the reorganization, in accordance with Section 251(g) of the DGCL, the remaining previous convertible and non-convertible debt of ENZC is debt of the Predecessor and convertible into shares of the non-public subsidiary or payable by the Predecessor rather than the Parent.
3. On November 16, 2020 the Company entered into debt exchange agreements with Seacor Capital, Inc., and Sky Direct, LLC whereby the balance of their outstanding notes and accrued interest were exchanged for Preferred Series C shares of ENZC extinguishing the debt obligation.

4) Financial Statements

A. The following financial statements were prepared in accordance with:

☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)[9]: Name:
Jona Barnes, E. A., Partner
Title: Partner
Relationship to Issuer: None

[9] The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

C. Balance sheet;
D. Statement of income;
E. Statement of cash flows;
F. Statement of Changes in Shareholders' Equity
G. Financial notes; and
H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial Statements are Incorporated by reference uploaded 9/08/2022

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Enzolytics, Inc. is a Delaware corporation in the development stage. The Corporation was initially incorporated, under the name of T and T Homes Limited on July 28, 2004, in the United Kingdom. On November 25, 2004, the name of the Corporation was amended to be Falcon Media Services, Ltd. On November 12, 2008, the Company changed its name to Extreme Mobile Coatings Corp., Ltd., on February 23, 2009 the Company incorporated in Delaware as Extreme Mobile Coatings Worldwide Corp. On May 19, 2010, the Company changed its name to Structural Enhancement Technologies Corp. On November 16, 2012, the Company amended its name to Eco- Petroleum Solutions, Inc. to indicate a change in its business plan to expand its operations by entering into the renewable energy sector to conduct the business of blending, bottling, and distributing private label motor oil, transmission fluid, and related products for the automotive aftermarket.

On July 21, 2017, the Company submitted a Corporate Action requesting a name and symbol change, as a required by the merger agreement, to change the name of the Company from Eco-Petroleum Solutions, Inc. to Immunotech Laboratories, Inc. to indicate the Company's entrance into the Drug Development Industry for Immunotherapies. The request was subsequently withdrawn, and the merger agreement terminated.

On October 25, 2017, the Company's subsidiary Immunotech Laboratories, Inc. submitted a request to for the retirement of the Immunotech Laboratories, Inc. symbol IMMB from the OTC Market. The request was subsequently denied, and a deficiency letter issued resulting in the termination of the merger agreement with ECPO.

On January 15, 2018, the merger agreement with Immunotech Laboratories, Inc. was terminated except for Section 1.03(d)(i) which relates to the appointment of Harry Zhabilov as Chairman and CEO of ECPO which remained in effect.

On January 30, 2018, a new Corporate action was filed by the Company to change its name from Eco-Petroleum Solutions, Inc. to Enzolytics, Inc. to better represent the new business strategy. The Corporate action was approved on March 22, 2018, and the ticker symbol was changed from ECPO to ENZC. The amendment to the Articles of Incorporation in the state of Delaware were filed on January 17, 2018 changing the name to Enzolytics, Inc.

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.

On June 25, 2018, the Company entered into a settlement agreement and stipulation ("Settlement Agreement") with Livingston Asset Management LLC ("Livingston") in connection with the settlement of $563,000 of bona fide obligations the Company owed to certain of its creditors. The Settlement Agreement was subject to Federal court fairness hearing, and on August 21, 2018, a federal court granted approval of the Settlement Agreement. If satisfied in full, pursuant to the Settlement Agreement the Company shall reduce the Company's debt obligations in exchange for the issuance of 563,000,000 shares of Company's common stock, in multiple tranches, pursuant to the terms of section 3(a)(10) of the Securities Act of 1933, as amended. At no time may Livingston beneficially own more than 9.99% of the Company's outstanding common stock. In connection with the transaction, the Company issued to Livingston a convertible promissory note in the principal amount of $100,000 bearing interest of 10% per year to cover legal fees and other expenses, The Note was convertible into shares of the Company's common stock at 50% of the lowest closing bid price for 10 trading days prior to the date of conversion. Under the terms of a separate engagement letter, in connection with the settlement agreement, the Company is to pay a registered placement agent ten percent (10%) of the dollar amount of creditor obligations extinguished pursuant to the settlement agreement. As of September 7, 2022, all 563,000,000 from the settlement agreement have been converted.

On April 16, 2020, the Company announced its new physical address and telephone number, 2000 N. Expressway, Unit 104, Plano, Texas 75074, telephone number, (972) 292-9414.

On April 30, 2020, the Company filed Foreign Profit Corporation Article of Continuance pursuant to Wyoming Statute W.S. 17-16- 1810 to redomicile the Company from Delaware to Wyoming and increasing the authorized common shares to three billion. On May 21, 2020, the Company was approved by the State of Wyoming.

On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapy, Inc., a biotech company located in Dallas, TX, announced the execution of a Letter of Intent to merge the two entities together with the intent to combine the two proprietary technologies to evaluate the beneficial and synergistic effect of combining therapeutics of the two entities to treat those infected with the HIV virus.

On October 22, 2020, the Company announced the appointment, by the Board of Directors of the Company, on October 20, 2020, of Charles Cotropia to the position of CEO of Enzolytics. Mr. Cotropia also serves as CEO of the Company's Merger target BioClonetics Immunotherapeutics, and Harry Zhabilov the former CEO of the Company has taken the position of CSO. Charles Cotropia was appointed to the Company's Board of Directors on October 1, 2020. Simultaneously, Harry Zhabilov was appointed to the BioClonetics Immunotherapeutics board.

On November 4, 2020 the Company elected to bring the Company back into good standing in Delaware rather than complete the redomicile to Wyoming.

On November 16, 2020, the issuer (having been renamed, immediately prior to this Holding Company Reorganization, from "Enzolytics, Inc." to "ENZC SUB, Inc.") completed a corporate reorganization (the "Holding Company Reorganization") pursuant to which ENZC SUB, Inc., as previously constituted (the "Predecessor") became a direct, wholly-owned subsidiary of a newly formed Delaware corporation, Enzolytics, Inc. (the "Holding Company"), which became the successor issuer. In other words, the Holding Company is now the public entity. The Holding Company Reorganization was effected by a merger conducted pursuant to Section 251(g) of the Delaware General Corporation Law (the "DGCL"), which provides for the formation of a holding company without a vote of the stockholders of the constituent corporations.

In accordance with Section 251(g) of the DGCL, Enzolytics Merger Corp. ("Merger Sub"), another newly formed Delaware corporation and, prior to the Holding Company Reorganization, was an indirect, wholly owned subsidiary of the Predecessor, merged with and into the Predecessor, with the Predecessor surviving the merger as a direct, wholly owned subsidiary of the Holding Company (the "Merger"). The Merger was completed pursuant to the terms of an Agreement and Plan of Merger among the Predecessor, the Holding Company and Merger Sub, dated November 16, 2020 (the "Merger Agreement").

As of the effective time of the Merger and in connection with the Holding Company Reorganization, all outstanding shares

of common stock and preferred stock of the Predecessor were automatically converted into identical shares of common stock or preferred stock, as applicable, of the Holding Company on a one-for-one basis, and the Predecessor's existing stockholders and other holders of equity instruments, became stockholders and holders of equity instruments, as applicable, of the Holding Company in the same amounts and percentages as they were in the Predecessor prior to the Holding Company Reorganization.

The executive officers and board of directors of the Holding Company are the same as those of the Predecessor in effect immediately prior to the Holding Company Reorganization.

For purposes of Rule 12g-3(a), the Holding Company is the successor issuer to the Predecessor, now as the sole shareholder of the Predecessor. Accordingly, upon consummation of the Merger, the Holding Company's common stock was deemed to be registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12g-3(a) promulgated thereunder.

The Holding Company adopted a certificate of incorporation (the "Certificate") and bylaws (the "Bylaws") that are, in all material respects, identical to the certificate of incorporation and bylaws of the Predecessor immediately prior to the Holding Company Reorganization, with the possible exception of certain amendments that are permissible under Section 251(g)(4) of the DGCL. The Holding Company has the same authorized capital stock and the designations, rights, powers and preferences of such capital stock, and the qualifications, limitations and restrictions thereof are the same as that of the Predecessor's capital stock immediately prior to the Holding Company Reorganization.

The common stock of the Holding Company trades on OTC Markets under the symbol "ENZC" under which the common stock of the Predecessor was previously listed and traded. As a result of the Holding Company Reorganization, the common stock of the Predecessor will no longer be publicly trade.

On November 30, 2020, Enzolytics, Inc. (the "Company") entered into a Business Combination Agreement with Bioclonetics Immunotherapeutics, Inc., ("Bioclonetics") a Texas Corporation controlled by Charles S. Cotropia, the Company's current Chief Executive Officer.

As consideration for the Business Combination, and in exchange for 100% of the issued and outstanding stock of BioClonetics, the Company has agreed to issue a total of 204,430,000 newly issued shares of Series B Preferred Stock to Charles S. Cotropia, and other Bioclonetic's Designees and 90,570,000 shares of newly issued Series B Preferred Stock to Harry Zhabilov, the Company's current Chief Financial Officer. These shares were issued on December 7, 2020.

In addition, on November 30, 2020, the Zhabilov Trust, the Company's Controlling Shareholder, entered into a Control Block Transfer Agreement, under which the Zhabilov Trust has agreed to transfer 35,100,000 shares of Series A Preferred Stock and 231,000,000 shares of Common Stock (together the "Control Block") to Charles S. Cotropia and other Bioclonetic's Designees. This reallocation of shares from Zhabilov Trust was completed on December 31, 2020.

After such share issuances and transfers we completed, Charles S. Cotropia became the Company's new Control Block holder and majority shareholder, in addition to his role as Chief Executive Officer of Enzolytics, Inc., resulting in a Change of Control.

In addition, on November 16, 2020 the Company entered into debt exchange agreements with Seacor Capital, Inc., and Sky Direct, LLC whereby the balance of their outstanding notes and accrued interest were exchanged for Preferred Series C shares of ENZC extinguishing the debt obligation.

As a result of the reorganization, in accordance with Section 251(g) of the DGCL, the remaining convertible and non-convertible debt of ENZC is now debt of the Predecessor and payable by or convertible into shares of the non-public subsidiary.

Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.

Two Patent License Agreements

On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV- BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.

Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.

Provisional Patent for Immunotherapy Treatment of Multiple Sclerosis

On December 9, 2020 the company filed a provisional patent with the U.S. Patent Office for an Immunotherapy treatment of Multiple Sclerosis developed by Harry Zhabilov, titled **NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR,** Ser. No. 62/123341. The Company received confirmation of filing from the U.S. Patent Office on December 10, 2020. On January 19, 2021 the Company announced the receipt for the Multiple Sclerosis Patent Application.

Engagement of BTS Research for Planned Toxicity Test

On December 14, 2020, the Company engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. The Company is still in the planning stages and based on the Mutual Recognition Agreement between the European Medicines Agency and the U. S, Federal Drug Administration may pre-empt the need for additional planned toxicity study. The toxicity study began in July 2022 and is currently ongoing at the time of this filing.

Texas A&M Facilities

Effective December 1, 2020, the Company entered a lease with Texas A & M University for office and laboratory space on the campus of Texas A&M University in the University's Institute for Preclinical Studies in order to expand the Company’s development capabilities for the production of additional monoclonal antibodies.

Discovery of Seven Newly Identified Conserved Target Sites of the HIV Virus.

On February 1, 2021, the Company announced the discovery, using Artificial Intelligence, of seven new expected immutable sites on the virus.

In Vitro Test Results for IPF Against Human Corona Virus 229E Strain (HCoV-229E)

In Vitro test result on the IPF peptide treatment against human corona virus strain 229-E from the Bulgarian National Centre of Infectious and Parasitic Diseases conducted by Petia Genova-Kalou were reported on February 16, 2021. The test results exhibited comparable efficiency but with 20-fold lower toxicity than the widely used anti-influenza medicine, Tamiflu.

In Vitro Test Results for IPF Against Herpes Simplex Virus (HSV-1)

In-Vitro test results from the Bulgarian National Centre of Infectious and Parasitic Diseases conducted by Petia Genova-Kalou were reported on February 16, 2021, on the IPF peptide (IPF). The tests did not show toxicity to cells and effectively inhibited the infectious HSV-1 virus. Furthermore, it was more effective than Acyclovir and had no toxicity effects on Acyclovir.

Discovery of Eleven Newly Identified Conserved Target Sites of the SARS-CoV-2 Virus (Coronavirus).

On February 22, 2021, the Company announced the discovery and Patenting, using Artificial Intelligence, of eleven new expected immutable sites on the SARS-Co-V-2 (Coronavirus) virus. The patents are described as CORONAVIRUS ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO, U.S. Application No. 63/152,084, Filing Date: February 22, 2021.

The application covers discoveries relating to the field of viral vaccines and therapeutics, and in particular, discloses antigens and epitopes of SARS-CoV-2, the causative agent of COVID-19. The identified antigens and epitopes of SARS-CoV-2 (the Coronavirus) claimed as used to produce binding proteins (e.g., antibodies) and in vaccines for treating, preventing, or reducing the risks of infections caused by β-coronaviruses such as SARS-CoV-2.

The application covers and claims discovered highly conserved antigens and epitopes of SARS-CoV-2, binding proteins (e.g., antibodies) that bind to the disclosed antigens and epitopes, vaccines based on the antigens, and methods of treating, preventing, or reducing the risks of infection with the antigens or binding proteins.

Provisional Patent for Monoclonal Antibodies

On March 18, 2021, the company filed a provisional patent with the U.S. Patent Office for Eight newly identified conserved target sites on the HIV-1 virus. The Patens are described as HUMAN IMMUNODEFICIENCY VIRUS (HIV) ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO, U.S. Application No. 63/162,853, Filing Date: March 18, 2021
The patent application is in the field of viral vaccines and therapeutics. It discloses and claims discovered antigens and epitopes of the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS). These antigens and epitopes of HIV are disclosed as used to produce binding agents (e.g., antibodies) and in vaccines for treating, preventing, or reducing the risk of HIV infection and the development of AIDS.

The application covers and claims discovered highly conserved antigens and epitopes of human immunodeficiency virus (HIV), binding agents (*e.g.*, antibodies) that bind to the disclosed antigens and epitopes, vaccines based on the antigens, and methods of treating, preventing, or reducing the risks of HIV infection with the antigens or binding proteins.

Filing of Updated NIH Grant Application

On March 22, 2021, the Company filed an updated NIH Grant application incorporating the newly conserved epitotes on both the HIV-1 and SARS-CoV-2 (coronavirus).

Issuance of Distributorship for India and multiple Eastern European Countries.

On May 12, 2021, the Company granted a distributorship license to a European pharma entity giving it the right to distribute the Company's anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia. The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity has invested $2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company $3 Million in cash plus a 50% ownership in the Licensing Entity. This agreement will result in establishing a committed partner for sale and distribution of the Company's ITV-1 therapeutic in the Licensed Territory as well as 50% ownership in Licensee and its profit derived from sales in the Licensed Territory.

Enzolytics, Inc. and Intel Corporation White Paper on Use of Artificial Intelligence

On May 17, 2021, Enzolytics Inc. and Intel Corporation published a thought leadership collaboration. The white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," highlights Intel's Artificial Intelligence Analytic tools and Enzolytic's innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.

Discovery of Conserved Immutable Target Sites on HTLV-1 Virus

The Company announced on May 26, 2021, that it had identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. Utilizing the Company's proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human anti- HTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies.

Additional Subscription of Preferred Series C

On June 6, 2021, Enzolytics CEO invested an additional $100,000.00 in a subscription for Series C Preferred shares.

Enzoytics, Inc. and International Medical Partners Ltd Engage Pharmalex, Clinic Design, Ltd. and Danhson Ltd for ITV-1 Clincal Trials and Permitting Process

On June 14, 2021, the Company announced the engagement by International Medical Partners Ltd (“IMPL”) of the Contract Research Organization (CRO) Clinical Design, Ltd and PharmaLex to prepare and establish a drug development program for the creation of protocols for human clinical trials that will lead to the licensing of the Company's ITV-1 therapeutic under the European Medicine Agency (EMA). The Company has contracted Danhson Ltd. to produce the initial quantities of ITV-1 to be used for preclinical and clinical trial purposes.

Board of Directors Appoints New Members

On June 16, 2021, the Company appointed Dr. Joseph P. Cotropia its Chief Science Officer and Dr. Gaurav Chandra its Chief Operating Officer to its Board of Directors.

VetProm Site Visit

On July 22, 2021, Chief Science Officer, Harry Zhabilov ("Zhabilov") completed ENZC's second visit to Sofia, Bulgaria where Zhabilov and ENZC's Bulgarian and US Consultants toured the manufacturing facility of VetProm, JSC (VetProm") , a wholly owned subsidiary of Danhson, LTD. This facility will be producing the ITV-1 compound for the clinical trials being conducted by Clinical Design Ltd. and all ENZC's future production needs. ENZC has purchased and shipped specialized equipment for installation at the facility as part of the manufacturing line for the ITV-1 immunotherapy treatment as well as the raw materials needed for the first clinical trial batch.

Appointment of Steve Sharabura as President of RobustoMed

On July 26, 2021 Steve Sharabura was appointed President of RobustoMed, Inc. RobustoMed received initial funding on November 12, 2021 for the implementation of its business plan to develop international markets for the Company's products in Central and Latin America.

Agreement entered with Danhson and Clinic Design for Clinical Trials

Enzolytics, Inc. completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) on July 29, 2021 to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization.

Master Service Agreement ("MDSA") and Product Specific Agreement – Development and Manufacturing Services ("PSA") entered into between Samsung Biologics Co., LTD. and Enzolytics, Inc.

On October 7, 2021, the Company entered into a MDSA and PSA with Samsung Biologics Co., Ltd to advance the development of the Company's human clone antibody program and clinical testing.

Installation of Equipment at VetProm Facility

Enzolytics, Inc. purchased and installed equipment necessary for production of the ITV-1 immunotherapy for the clinical trials being design by Clinic Design. The original equipment had to be returned because of damage to the centrifuge which, along with other issues encountered by IMPL, delayed the scheduled production expected in October. The new expected production date has been rescheduled for January of 2022.

Initial Funding for RobustoMed, Inc.

On November 12, 2021 RobustoMed, Inc. received the first funding for use in the implementation of its business plan to establish a foothold in Latin and Central America.

Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072

On November 17, 2021 announced planned production and sale in the U.S. and North America of "Enzolytics IPF Immune", a liquid nutritional supplement that is an immune modulator that benefits the immune system by fortifying it against infections and supporting the body's antioxidant defense. The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083. The product will be produced and sold by the Company pursuant to its license under U.S. Patent No. 8,309,072 (the '072 Patent).

Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic

On December 29, 2021, Enzolytics, Inc. engaged Scendea USA, Inc. (www.scendea.com), a leading international product development and regulatory consulting group, to advance its anti-HIV therapeutic ITV-1 to production, clinical trials and market approval under both the European Medicines Act (EMA) and the U.S. FDA regulatory process. Scendea is a leading product development and regulatory consulting group serving the pharmaceutical and biotechnology industry. Scendea's service will focus on reducing time-to-market and minimizing development costs.

Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System

January 4, 2022, the Company announced the production and sale in the U.S. and North America of "Enzolytics IPF Immune™," a science-backed liquid nutritional supplement that acts to strengthen the body's immune system. The immune modulator benefits the immune system by fortifying it against infections.

Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market

Enzolytics announced its plans for entry into the diagnostics market on February 21, 2022. The Company filed a comprehensive U.S. and foreign Patent Cooperation Treaty (PCT) Patent Application covering its invention of a novel, innovative technology for improved diagnostics. The PCT Application covers the Company's identification of highly conserved antigens and epitopes of SARS-CoV-2 that can be used in vaccines and to produce bindings proteins (e.g., antibodies) for treating, preventing, or reducing the risks of infections caused by β-coronaviruses such as SARS-CoV-2. The patent also covers the discovery of using these identified antigens and epitopes as targets for detecting and diagnosing SARS-CoV-2 infection.

Enzolytics, Inc. Announces New Advisory Board Member

On February 28, 2022, Dr. Suraj Kumar Saggar accepted an invitation from the Company to join its Advisory Board. Dr. Saggar brings to the Company his vast experience as a physician and healthcare research professional with an established track record of exceptional performance in healthcare operations, clinical trials, and regulatory compliance.

Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market

On March 10, 2022 the Company announced that Enzolytics IPF Immune™, its immune modulator, will be introduced into the U.S. market in late March 2022. The product has been produced and is waiting finally regulatory approval on a label change.

Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti- HIV Therapeutic for Use by Patients in African Regions

On March 14, 2022 . the wholly-owned subsidiary Virogentics, Inc. (the "Subsidiary") of Enzolytics announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS.

The steps necessary for the production and delivery of the Company's anti-HIV therapy in these regions are in progress. Toxicology, pharmacodynamic and pharmacokinetic studies (toxicology studies) of the immunotherapy are planned, a prerequisite to use of the immunotherapy in certain African countries where the therapies will be used.

Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS- CoV-2 and HIV Viruses

In the submissions, under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending in its international patent applications, covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients the applications allow the Company to prosecute the applications both in the U.S. and in all PCT member countries. The applications identify and claim the conserved, immutable sites on the SARS-CoV-2 virus and HIV virus that have been identified by the Company through its Artificial Intelligence (AI) technology.

B. Please list any subsidiaries, parents, or affiliated companies.

The Company is a 49% owner of the Bulgarian entity IMMB BG, which held a sub-license agreement issued by ENZC for the proprietary immunotherapy treatment until it was terminated in the second quarter of 2021 and the investment written off as worthless in the yearend 2021 financials.
The Company is 100% owner of
Biogenysis, Inc. The Company is 100%
owner of Virogentics, Inc. The
Company is 100% owner of Robustomed, Inc.
The Company is 100% owner of BioClonetics Immunotherapy, Inc.
The Company is 50% of International Medical Partners LTD (A Bulgarian entity)

C. Describe the issuers' principal products or services, and their markets.

The Company's products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies and an artificial intelligence (AI) platform heath care development.

Enzolytics has proprietary technology for creating human cell lines that produce fully human monoclonal antibodies against numerous infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus, and diphtheria. The Company's technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS- CoV-2 (Coronavirus) monoclonal antibodies for treating COVID-19. The Company plans to employ its technology to subsequently produce fully human monoclonal antibodies for treating HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease and the Ebolavirus.

The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as "Clone 3") which has been shown in *in vitro* tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).

Using AI, the Company has also identified 8 additional conserved sites on the HIV-1 virus, some with over 98% conserved sequences, against which the Company plans to produce anti-HIV monoclonal antibodies. Production of multiple antibodies targeting different conserved and expectedly immutable sites comports with experts' conclusion that an effective treatment for HIV and the Coronavirus will likely require the administration of multiple monoclonal additional antibodies. Effective monoclonal antibodies will be those that target conserved and expectedly immutable virus sites. Producing targeted antibodies will result in the production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. In other words, even a "variant form of the virus" will expectedly contain the immutable targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that nutates.

While the Company's HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS, they may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current antiretroviral therapy for several significant reasons:
(1) the therapy will be non-toxic (without damage to the kidneys and liver) and will not cause bone density deterioration (osteopenia and osteoporosis) – as does antiretroviral treatments, (2) will not require lifetime treatment and (3) will be far less expensive.

Using its proprietary methodology, the Company is also producing anti-SARS-CoV-2 monoclonal antibodies and has identified 19 conserved, expectedly immutable epitopes on the Coronavirus against which it plans to produce targeted monoclonal antibodies. Using AI, the Company has screened over 2 Million Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 19 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed by the Company using AI.

Comprehensive patent protection covering these discoveries, relating to HIV, the Coronavirus, and use of AI to guide production of antibodies have been filed under the Patent Cooperation Treaty (PCT) to seek coverage in the U.S. and in member countries of the PCT, In these PCT Patent Applications, the Company has claimed its discoveries relating to both HIV and the SARS CoV-2 (Coronavirus) including the use of these identified conserved epitopes for (1) producing a therapeutic monoclonal antibody to treat HIV or the CoronaVirus, (2) producing a vaccine against HIV or the CoronaVirus, or (3) for use in any diagnostics to identify whether a person has HIV or the CoronaVirus. In this way, the patent coverage sought includes patent claims on the discovered epitope/antigens, vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to the epitope/antigens.

The Coronavirus treatment drug market is expected to grow from 15.9 billion in 2020 to over $49.2 billion in 2027. The HIV Drug Market is expected to reach $36.49 billion by 2027 for a total market size of $85.69 for the treatments under development, The Company expects, aided by the continued use of AI, further expansion of its pipeline of additional treatments for other life threatening and debilitating viruses both in humans and in animals.

Another therapeutic newly introduced into the U.S. market by the Company is a dietary supplement sold under the brand IPF Immune™. IPF Immune™ supports the body's immune system promoting normal immune function – important for good health.

The following attributes have been identified as provided by the IPF Immune therapeutics:

- Enzolytics IPF Immune™ may be combined with anti-inflammatory drugs, antiviral, antibacterial, and antimycotic treatment to support the immune system.
- IPF has similar clinical benefit of Acyclovir (for treating Herpes), Tamiflu (for treating Influenza) but those therapies were found to be 35 times more toxic to the body.
- Beneficial in viral diseases: viral hepatitis, influenza, cytomegalovirus or herpes infections. oncological diseases. complex therapy of infectious-inflammatory diseases, and opportunistic infections.
- Beneficial in non-specific pulmonary infections such as pneumonia, chronic obstructive pulmonary disease, chronic bronchitis, laryngitis, or laryngotracheitis. Balancing the work of the immune system after influenza infections or coronaviruses infections.
- Demonstrated very good tolerance in all patients and absence of side effects

Company Update

ITV-1 anti-HIV Therapeutic

The Company's ITV-1 anti-HIV therapeutic is in production and the Company is proceeding with steps to advance it through approval under the European Medicines Act (EMA). Toxicology studies are ongoing and near completion in the Company's partnering California lab. The results of these tests will be reported as they are completed. Simultaneously, the ITV-1 therapeutic is proceeding through the necessary multi-stage production process in the Company's partnering lab in Europe. The current ongoing production of ITV-1 will be used in clinical trials conducted under the EMA guidelines. Early production of ITV-1 will be submitted to health care entities in Africa, where testing and use of the therapeutics are expected to be made possible before EMA approval.

To meet EMA requirements, the Company has engaged European medical specialists to guide the therapeutics through the EMA process. The Company's Board Advisor, Dr. Lachezar Ivanov, and the Company CSO Harry Zhabilov, in conjunction with medical field advisors in Europe, are managing this process for introducing ITV-1 to E.U. countries under the EMA.

The Company is also focused on providing its anti-HIV therapeutics to the African continent due to the tremendous need in African countries for effective and affordable treatment. The Company plans to make ITV-1 available in countries in Africa, including Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa and the Company is coordinating the introduction of ITV-1 for use in these countries as soon as possible. This is significant, recognizing that out of the 39 million HIV-positive people worldwide, 69% live in sub-Saharan Africa. There are roughly 23.8 million infected persons in all of Africa. In addition, 91% of the world's HIV-positive children live in Africa. More than 45% of the African population who have HIV do not have any access to the anti-retroviral treatment used in other countries to treat but not cure HIV.

The beneficial effects of ITV-1 are significant and will be complimentary to other treatments but at a lower cost and available to the over 45% of infected individuals in Africa who have no access to any treatment, including antiretrovirals which are used in other countries around the world for treating HIV patients.

Positive Therapeutic Effects of ITV-1

Prior European clinical trials have demonstrated the following beneficial effects of ITV-1.

- ITV-1 inhibits the infection of CD4 T-cells by HIV.
- It reduces HIV viral loads.
- Replaces or complements current anti-retroviral therapies.
- It is potentially less costly and much less toxic.
- It may be effective as a periodic therapy instead of a daily one.
- It is unaffected by HIV mutations that can hamper anti-retroviral therapies (HAART).
- Tests have shown an 80.5% drop in viral loads.
- It raises CD4 T-cell counts to healthier levels, with a 68% increase in CD4+T-lymphocytes.
- Use achieved an increase in the CD4/CD8 index.
- It demonstrated an excellent effect on opportunistic infections.

- It had good compatibility with other anti-retroviral drugs.
- There was good tolerance without any side effects.
- Use resulted in a decrease in the absolute number and the relative percent of CD8 lymphocytes.
- It boosts the immune system to fight HIV infections.

ITV-1 has benefits that anti-retrovirals do not and may be used in situations where anti-retrovirals are not appropriate.

- Anti-retroviral therapies have serious side effects. In addition, they do not cure a patient.
- HIV infections are most treatable during their earlier stages, and patients cannot take antiretrovirals during earlier stages since drug resistance often develops.
- There are limited or few treatment options available when viral load and CD4 cell counts are at their worst, i.e., AIDS.

The Company's IPF Immune ™ dietary supplement

Enzolytics IPF Immune™ will be available in numerous sales outlets throughout the U.S. Delays in producing sufficient quantiles for the market are being addressed. These delays have provided time for increasing production capability to meet demand. The company's market research has indicated significant demand for IPF Immune™.

The nutritional supplement market is large and growing annually. The global dietary supplements market was valued at $151.9 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030. Over the forecast period, increasing consumer awareness of personal health and wellbeing is expected to be a key driving factor for dietary supplements. In addition, increasing dependence on supplements to fulfill the nutrient requirements owing to their high convenience is expected to drive the market upwardly over the forecast period. The U.S. market for dietary supplements leads the North American market and matches the European market.

The Company is making plans for the sale of the IPF Immune™ product in numerous countries in Europe, Latin America, Australia, and Canada. These plans include engaging with promoters and distribution representatives in these countries. Just like in the U.S., each country's nutritional supplement market is large and growing rapidly. In addition, because the product is produced in Europe, providing the product to European markets will be easier and less expensive, providing a more significant profit margin to the Company.

Regarding marketing, the Company has engaged a marketing specialty firm that will use "computer analytics" to target individuals who are specifically searching for a nutrition supplement with the properties of IPF Immune™. Such focus will greatly increase sales of this new product while reducing advertising costs.

Production of Monoclonal Antibodies

Enzolytics' U.S. lab at the A&M Institute for Preclinical Studies is focused on producing fully human monoclonal antibodies targeting multiple infectious diseases, including SARS-CoV-2, HIV-1, Feline Leukemia virus and Feline Immunodeficiency virus. The lab uses the Company's proprietary methodology for producing fully human monoclonal antibodies which target conserved, immutable sites on the viruses, thereby avoiding ineffectiveness due to virus mutation.

The methodology implemented by the Company to produce monoclonal antibodies is proprietary and the subject of pending international patent applications. In the initial process step, Artificial Intelligence (computer analysis - A.I.) is used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary A.I. platform invented by Dr. Gaurav Chandra the Company COO. In the A.I. initial analysis step, the sequences (structure) of over 2 million Coronavirus isolates have been analyzed. From that analysis, 19 epitopes (target sites) have been identified as immutable and conserved across all 2 million isolates. The Company production process is then employed to produce monoclonal antibodies targeting these identified conserved sites.

As a part of this process, 3 Dimensional models of these conserved targets are generated, and the targets are analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Then Enzolytics' scientists produce multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus.

Enzolytics' methodology for producing monoclonal antibodies is innovative, unlike those employed by other biotech companies. The Company's antibodies are produced from human "immune-B cells," obtained from convalescent individuals who have recovered from the target virus. The Company's monoclonal antibodies are not "humanized" but are fully human monoclonal antibodies where the original antibody affinity and specificity are maintained, and the chances of immunogenicity are minimized.

The team then produces broadly neutralizing antibodies using various techniques. The Company is partnering with a biotech company with specialized capabilities for accelerating process steps to speed production. This new strategy will allow the Company to reduce the time to completion significantly. In addition to the already produced anti-HIV monoclonal antibody Clone 3, the Company is focused on producing monoclonal antibodies for treating HIV-1, SARS-CoV-2, SARS-CoV-2, Feline Leukemia Virus (FeLV), and Feline Immunodeficiency Virus (FIV). However, the Company has identified the conserved and immutable epitope sites on 20 human and animal viruses, against which it plans to produce monoclonal antibodies for the treatment of those viruses.

This production process is highly technical and time-consuming. The process begins by creating the target epitopes identified using A.I. as sites fully conserved across millions of epitopes of the targeted virus. Then, the antibody creation process is conducted such that the produced antibodies are designed to neutralize by binding to these “Achilles heel” sites on the targeted virus.

Once produced, the monoclonal antibodies are tested for binding and neutralizing activity. These characteristics are confirmed by the Company's partnering laboratories, Genscript Labs, and the University of Strasbourg, France. After confirming antibody activity, the Company's CDMO partner Samsung Biologics produces recombinant antibodies in their proprietary, FDA-approved stable CHO cell line suitable for Clinical Application. https://www.bloomberg.com/press-releases/2021-10-07/enzolytics-inc-and-samsung-biologics- announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2.

The plans are in place to proceed with animal studies to demonstrate the *in-vivo* efficacy of the monoclonal antibodies in partnership with European partners.

There is a significant role for mucosal immunity and secretory as well as circulating IgA antibodies in COVID-19. Therefore, Enzolytics focus on mucosal immunity for COVID-19. Enzolytics firmly believe that mucosal immunity can be exploited for beneficial diagnostic, therapeutic, or prophylactic purposes.

Enzolytics has created Class switched IgA1/2 Clone 3 Antibodies. This therapy will expectedly provide a protective immunological defense against an initial exposure to HIV virus at mucosal surfaces, such as occurs in the passage of the virus from mother to child through maternal breastfeeding. HIV mucosal infection plays a critical role in virus transmission and AIDS pathogenesis, affecting mucosal surfaces of the gastrointestinal tract early on by depleting CD4+ T helper cells independently of the virus transmission route. Although current anti-retroviral therapy helps control HIV infection in most patients, it cannot eradicate the virus from the human host. Therefore, the development and use of HIV microbicides (i.e., topical pre-exposure prophylaxis) have become the most promising approach to preventing HIV transmission. Thus, the development of Class switched Clone 3 IgA1/IgA2 is highly significant.

Enzolytics is collaborating with companies to produce monoclonal antibodies for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV). Enzolytics has already identified a partner for the monoclonal antibodies targeting Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus.

Enzolytics Patent Portfolio and Strategy

As of August 19, 2022, the Company has three (3) pending Patent Cooperation Treaty (PCT) Patent applications covering its fully human monoclonal antibodies targeting the CoronaVirus and HIV. Additional patent applications are being prepared to cover the numerous viruses against which the Company plans to produce monoclonal antibodies.

In the first PCT Patent Office Official Action on the Company’s International Patent Application covering its discovery and exclusive claim to conserved antigens and epitopes of the HIV virus, the PCT International Search Report concluded that inventions claimed therein are novel and inventive and thus will expectedly be issued in final international patents. The Company’s International Patent application covers (1) the discovered highly conserved antigens and epitopes (sites) on the HIV virus, (2) antibodies that bind to the disclosed antigens and epitopes, (3) vaccines based on the antigens, (4) methods of treating, preventing, or reducing the risks of HIV infection with the antigens or binding proteins, and (5) methods and kits for detecting or diagnosing infection by HIV using the antigens or binding proteins.

The Company discovered the claimed virus sites through computer analysis (Artificial Intelligence (A.I.)), wherein tens of thousands of HIV isolates were curated to identify these critical, conserved, immutable epitopes on the virus. These sites are now claimed as patentable based on their novel specificity and the finding that they are conserved on the HIV virus. This is significant in that by producing antibodies that attack these conserved, immutable sites, the virus can be neutralized rather than unaffected due to virus mutation that avoids the therapeutic.

The Company is producing fully human monoclonal antibodies against these claimed sites. The International Patent Office has now confirmed these discoveries to be novel and inventive, capable of being patented and claimed exclusively for a 20-year term in every member country under the Patent Cooperation Treat in which the Company pursues these claims.

Due to the novel nature of the Company’s discoveries, the Company fully expects the same favorable results in the PCT Patent Office for its pending applications covering epitopes (binding sites) on the CoronaVirus (covering all variants), on the Monkeypox Virus, and on numerous animal viruses, namely Feline Leukemia Virus (FeLV), Feline Immunodeficiency Virus (FIV), Elephant Endotheliotropic Virus, Equine Infectious Anemia, and Koala Retrovirus. The Company fully expects the issuance of multiple international patents covering these discoveries.

The Company's PCT applications also cover the identification of highly conserved antigens and epitopes of these viruses that can be used in the production of antibodies and the production of vaccines for treating, preventing, or reducing the risks of infections caused by these viruses.

The patents also cover the discovery of using these identified antiragens and epitopes as targets for detecting and diagnosing viral infection. This is a signicant development since these patents cover treatment and prevention and target detecgting and diagnosing infections for all viruses pursued

In the Company's unique process, computer analysis (A.I.) was used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary A.I. platform invented by Dr. Gaurav Chandra, the Company COO. The sequences (structure) of over 87,500 HIV isolates were analyzed in the initial A.I. step for HIV, and for the Coronavirus, over 2 million SARS-CoV-2 virus isolates were curated. In the case of HIV, eight (8) epitopes (target sites) were identified and claimed in the Company's PCT application. As a part of this process, 3 Dimensional models of these conserved targets were generated, and the targets were analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. From this, Enzolytics' scientists are producing multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus. As a result, the monoclonal antibodies produced against these targets will be universal, durable, broadly neutralizing, and unaffected by virus mutation. In the case of SARS-CoV-2, nineteen (19) conserved sites were identified and are claimed in the Company's pending PCT applications.

The Company considers the forthcoming patent protection highly significant in view of the following facts:

- For a monoclonal antibody to be effective (that is, to be fully capable of neutralizing a virus), it must target an immutable site on the virus. Otherwise, a virus mutation will render the therapeutic ineffective.
- The Company has analyzed over 2 million Coronavirus isolates and over 87,000 HIV isolates and has identified 19 conserved sites (98 to 99% conserved) on the Coronavirus and 8 conserved sites on the HIV virus.
- The Company's patent claims cover these findings. From the most recent PCT International Patent Office Action, claims have been recognized as novel and Inventive. They thus can be expected to issue in the U.S. and many foreign countries pursued. The Company claims the use of anyone identified epitope or any combination of any of the multiple identified epitopes in any of the following ways:
    - For producing a therapeutic monoclonal antibody to treat HIV or the CoronaVirus.
    - For producing a vaccine against HIV or the CoronaVirus.
    - For producing related prophylactic/therapeutic methods relating to the epitopes/antigens.
    - For use in any diagnostic test to identify whether a person has HIV or the Coronavirus.

To accelerate and fully execute the successful production of the multiple monoclonal antibodies, the subject of the Company's intellectual property (specifically the numerous monoclonal antibodies (mAbs) targeting both human and animal viruses), the Company continuously engages with numerous entities to accelerate its progress toward production, testing, and delivery of successful therapeutics. Entities with whom the Company is working include other Biotech Companies having:

- Technology and processes for accelerating the production of monoclonal antibodies that target critical virus sites identified by the Company using its A.I. platform. The Company has identified critical conserved target sites on 20 viruses, including human and animal viruses, and is engaging with biotech companies having expertise in accelerating the production of such antibodies.
- Related, synergistic or complimentary therapeutics and business structure for the purpose of potential combination with other biotech entities.
- Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise target sites on both the Coronavirus and HIV viruses which are then used in the Company’s Texas lab against which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.
- Specialized cell sorting technology that is complementary to the process used in the Company’s lab to accelerate production of mAbs for advancing production.
- Expertise in hybridoma production techniques for producing mAbs using hybridoma methodologies complementary to the process used in the Company's lab.
- Animal trials centers, both in the U.S. and abroad, for the preparation of animal trials.
- Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the substantial funds needed for the production of the recombinant mAbs necessary for future trials and for conducting animal trials.

As to each of these entities and those with whom the Company currently works on an ongoing basis, the Company has entered into NDAs (Nondisclosure Agreements) necessary to preserve and protect the Company plans and intellectual property being discussed and exchanged between the parties. These contractual restrictions are critical for the Company and its partners. Maintenance of strict confidentiality is essential to preserving intellectual property rights (patent rights) which are now being sought and will be sought in the future. Premature disclosure of information can bar the right to seek patent protection at a later date. The Company is not able to share specific details regarding arrangements regarding these NDAs.

The term of these NDAs is not time limited. The term extends until the later of five (5) years from the Effective Date or "until such time as the proprietary information is publicly known and made generally available". This provision is necessary because under Patent Laws an issued patent may be invalidated where the patent is filed subsequent to public disclosure of the invention claimed. In view of this limitation, the Company makes no public disclosure of information subject to NDAs and inventions covered by them.
Additionally, certain technical information shared with companies with whom the Company has entered into an NDA may not be included in a patent application, but rather the subject technical information is maintained as Company confidential ("secret") indefinitely. Also, in these Agreements, the parties generally agree not to reveal the names of the contracting parties for a specified period.

The Company is very confident in its Artificial Intelligence empowered Intellectual Property Portfolio. It has allowed the Company to claim exclusive rights on an international stage covering critical target sites on numerous human and animal viruses. This places the Company on an equal level with the largest biotech companies in that the Company is the first to identify and patent critical sites on many human and animal viruses. This same technology and strategy are being implemented by the Company on new viruses, human or animal. The Company identified the conserved sites on the Monkeypox Virus even before the World Health Organization declared it a global health emergency last week.

The Company believes that its extensive patent portfolio will provide a return on investment through partnering or licensing technology covered by multiple international patents.

Enzolytics Artificial Intelligence Platform

Enzolytics has a wholly owned Artificial Intelligence platform that:

1. Permits early drug discovery and development

2. Builds an Intellectual Property Portfolio

3. Provides for strategic entry into the personalized medicine market

The Artificial Intelligence platform is being built under the leadership of Dr. Gaurav Chandra., the Company's COO. The Healthcare A.I. market is expected to be $34 Billion in 5 years. This platform makes possible:

1. Creation of an artificial intelligence platform for Genomic Surveillance and monitoring of virus epidemiology
2. Application of A.I. to analyze the amino acid sequences of the targeted viruses to identify conserved immutable and neutralizable sites on the targeted viruses.
3. A comprehensive A.I. protocol for the production of monoclonal antibodies, including implementing A.I. Analysis of existing viruses and any new virus immediately upon its emergence globally.
4. Collaboration with biotechnology companies and veterinary institutions in early drug discovery and development programs, increasing safety, efficacy, and probability of success.
5. An envisioned consortium to assess the effects of Genetics, Nutrition, and Human Microbiome on infectious diseases, mental health disorders, and chronic medical diseases.
6. Collaboration with technology companies to offer solutions with Global Pandemic Preparedness

Enzolytics A.I. platform is unique because it has been driving the Company's discoveries and drug development. A.I. has helped Enzolytics move beyond big pharma's monoclonal antibody discovery and development. As a result, Enzolytics continues to forge ahead with the immediate strategy to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostics tests, and expand the Company's Patent portfolio. Enzolytics' long-term plan is to be a serious contender in the personalized medicine market. Enzolytics continues to partner with technology, genetics, diagnostic and regulatory companies with that strategy in each of these areas:

1. Artificial Intelligence Platform for Genomic Surveillance and monitoring of virus epidemiology

2. Application of A.I. to analyze the amino acid sequences of the targeted viruses to identify conserved immutable and neutralizable sites on the targeted viruses. An extensive A.I. analysis of 2.8 million SARS-CoV-2 isolates confirmed the 19 immutable sites to be conserved in ALL Variants of Concern and Variants of Interest. The Company's Artificial Intelligence platform has been used to build 3D Models of all the 19 conserved targets. The analysis of the SARS-CoV-2 spike protein revealed that all epitopes identified by the Company are **linear** on the spike proteins, **accessible** by antibodies, **neutralizable**, and **unaffected by mutations**. An extensive A.I. analysis of 87,500 HIV isolates and confirmed 8 immutable sites on the HIV virus. A.I. confirmed the KLIC amino acid binding site sequences targeted by the Company's primary anti-HIV monoclonal antibody is 100% conserved. The KLIC binding site on the HIV virus has remained unchanged for decades, as confirmed by the Company's analysis of the Los Alamos National Database of HIV sequences. This means that even mutations of the HIV virus will contain this neutralizable site, and virus escape will not occur in treatment with the Company's anti-HIV antibody.

3. A comprehensive A.I. protocol for producing monoclonal antibodies, including implementing A.I. analysis of existing viruses and any new virus immediately upon its emergence globally. Dr. Chandra discusses the significance of this protocol in an article published in The Yuan on December 20, 2021. https://www.the-yuan.com/191/AI-Provides-Key-to-Pandemic-Preparedness.html

4. Collaboration with biotechnology companies and veterinary institutions in early drug discovery and development programs, increasing safety, efficacy, and probability of success. A joint paper published by Enzolytics in conjunction with Intel Corporation provides more details regarding this collaboration.
https://www.intel.com/content/www/us/en/healthcare-it/resources/enzolytics- whitepaper.html

5. Enzolytics A.I. Human Microbiome Consortium.

A.I. is a significant driver for advancing healthcare. Understanding the Human Microbiome will be pivotal to that transformation, to unlock the potential of the Human Microbiome by utilizing Artificial Intelligence.

Enzolytics is building on the consortium to utilize A.I. to assess the effects of nutrition, genetics, and the human microbiome on diseases. This is a part of the Company's long-term strategy to enter the personalized medicine market and build a strong I.P. portfolio.

1. Build prediction models for infectious diseases (preferably COVID), mental health disorders, and chronic medical diseases.

2. Identify biomarkers for infectious diseases and chronic medical diseases.

3. Identify novel targets and clear intervention strategies for infectious and chronic medical diseases.

A.I. Driven Diagnostics

Enzolytics is developing Artificial Intelligence for use in *in-vitro* diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations. Enzolytics has identified conserved targets for many infectious diseases for humans and animals. The Company has identified conserved targets for Monkey Pox, SARS-CoV-2, HIV, rabies, influenza A, influenza B, HTLV1, Herpes, Smallpox, Ebola, Equine Infectious Anemia, Feline leukemia virus, Feline immunodeficiency virus, and Koala Retrovirus. The Company published information regarding these findings in its Press Release on February 21, 2022.
https://www.accesswire.com/viewarticle.aspx?id=689605.

Documented studies show better clinical outcomes and delayed progression of diseases if patients have the antibodies to the conserved targets. Enzolytics is working on prognostic tests utilizing A.I. to predict the immune response before receiving viral therapy. This will allow physicians to understand if a patient will respond to a particular antiviral treatment. More information on this technology has been presented by Dr. Chandra, the Company's COO, published in The Yuan on April 4, 2022. https://www.the- yuan.com/269/AI-Driven-Diagnostics-Transform-Healthcare.html.

Enzolytics Advisory Board

Enzolytics continues to build a strong Advisory Board to support Enzolytics' leadership team in achieving the Company's goals and mission. In addition, the Company's Advisory Board is instrumental in fostering innovation and interfacing with potential biotech partners both in the U.S. and abroad.

Company Programs Funding

Given the large number of therapeutics being advanced by Enzolytics, the Company is focused on raising the necessary funds for the production and sale in the U.S. and abroad of IPF Immune™, final development of its anti-HIV ITV-1 therapeutic, accelerating the development of multiple monoclonal antibodies for human therapy, and production of animal monoclonal antibodies. The Company's audit is being finalized, and the Company fully expects to be able to acquire the funding necessary to complete its multiple programs.

.**6) Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties, or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company leases a 380 sq ft facility located at 2000 North Central Expressway Plano Texas 75074 for $650.00 per month. The lease is for a one-year period ending on December 31, 2022. All lease payments are current.

In addition, the Company leases a 695 sq ft office and laboratory facility located at 800 Raymond Stotzer Parkway Building 1904, Suite 2106, College Station, Texas 77843 for $2,595.00 per month. The lease ends in December 2023. The lease is currently month to month. All lease payments are current.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Harry Zhabilov	CFO and CSO	Frisco, TX	190,750,000	Series B	42.84%	
Zhabilov Trust Diana Zhabilov Trustee	Shareholder	Frisco, TX	18,900,000	Series A	31.50%	
Charles Cotropia	CEO	Heath, TX	86,882,750 14,917,500 98,175,000	Series B Series A Common	19.52% 24.86% 3.51%	
Joseph Cotropia	CSO	College Station, TX	86,882,750 14,917,500 98,175,000	Series B Series A Common	19.52% 24.86% 3.51%	
Gaurav Chandra	COO	Cape Town, South Africa	30,664,500 5,265,000 34,650,000	Series B Series A Common	6.89% 8.78% 1.24%	

8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); **none**
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; **none**
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; **none**
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. **none**

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. The Company is litigating 2 pending matters

In Delaware, 2 In Federal Court and 1 in Chancery Court where there are disputed shares. The Company and its legal representatives believe all claims to be meritless and baseless and are vigorously defending the matters. The Company and its legal representatives believe they will prevail in all cases. The company prevailed in the Mergenthaler v. Enzolytics, Inc. case in Delaware Federal District Court.on August 17, 2022. Judge Andrews found in his memorandum opinion that "the plaintiff failed to state a plausible claim".

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers: Securities

Counsel

Name:	Morgan Petitti
Firm:	Morgan E. Petitti, ESQ
Address 1:	118 W. Streetsboro Rd.
Address 2:	Hudson, Ohio 44236
Phone:	330-697-5848
Email:	PetittiLaw@gmail.com

Accountant or Auditor

Name:	Jona Barnes, E.A. Partner
Firm:	Mallet & Barnes Tax Service
Address 1:	6136 Mission Gorge Road Suite 125
Address 2:	San Diego, CA 92120
Phone:	(619) 326-0840
Email:	jonabarnes117@gmail.com

Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: Steven Heumann
Firm: Eisner & Amper
Nature of Services: Consulting Accountant
Address 1: 111 Wood Avenue South
Address 2: Iselin, NJ 08830-2700
Phone: 212-949-8700
Email:

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Charles Cotropia, certify that:

1. I have reviewed this June 30, 2022 Quarterly Disclosure Statement of Enzolytics, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosurestatement.

September 8, 2022

/s/ Charles Cotropia, CEO

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Harry Zhabilov certify that:

1. I have reviewed this this June 30, 2022 Quarterly Disclosure Statement of Enzolytics, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosurestatement.

September 8, 2022

/s/ Harry Zhabilov, CFO

(Digital Signatures should appear as "/s/ [OFFICER NAME]")